Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

No Long-Term Benefit to Sentinel Lymph Node Biopsy in Most DCIS Patients

Publish date:: November 11, 2019

Key clinical point: Sentinel lymph node biopsy (SLNB) is not warranted in women with older patients with ductal carcinoma in situ (DCIS) amenable to breast conservation.

Major finding: With a median follow-up of 5.8 years, there were no significant differences in rates of recurrence, ipsilateral breast cancer, or breast cancer-specific mortality for SLNB versus no SLNB.

Study details: Retrospective study including 12,776 women aged 67-94 years who received a diagnosis of DCIS between 2001 and 2013 and underwent breast-conserving surgery.

Disclosures: The research was funded by an award from the Patient-Centered Outcomes Research Institute (PCORI). Dr. Wang reported no disclosures, while co-authors provided disclosures related to Genentech, Eisai, Pfizer, Jonhson & Johnson, and 21st Century Oncology.

Citation:

Hung P et al. JNCI Cancer Spectr. 2019 Aug 7;3(4):pkz052. doi. 10.1093/jncics/pkz052. https://academic.oup.com/jncics/article/3/4/pkz052/5544720

This Week's Must Reads

AGA releases BRCA risk guidance,

Heavy menstrual bleeding difficult to control in young patients with inherited platelet disorders,

Children rarely transmit SARS-CoV-2 within households,

Transitioning regimen may prolong proteasome inhibitor–based therapy for MM,

Interim PET/CT identifies poor-risk DLBCL patients after R-CHOP14,

Must Reads in Breast Cancer

Breast density asymmetry might increase breast cancer risk,

Lifestyle choices may reduce breast cancer risk regardless of genetics,

Novel SERD, LSZ102, shows promise for pretreated ER+ breast cancer,

Personalized cancer vaccine may enhance checkpoint inhibitor activity,

Beta-blocker use not linked to improved breast cancer prognosis,